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Abstract 
Purpose: To elucidate the outcomes of treatment and epidemiology of epilepsy related to glioma in a 
single center in Chinese patients. 
Methods: Prescription medicines usage and clinical data were collected from medical records of 119 
patients with gliomas between August 2009 and September 2015. Fisher’s exact and Chi square tests 
were used for analysis of seizure incidence differences as per WHO Grades, histology, location as well 
as tumour number, age and sex. 
Results: Preoperative seizures were noted in 33.8 % of glioma patients. After surgery, all the patients 
were given antiepileptic drugs (AEDs) prophylactically. Ten patients (8.4 %) developed seizures in the 
initial postoperative week, and 73 (61.3 %) patients at the last follow-up period. Overall, seizure 
incidence was 74.2 % in WHO Grade II, 68.4 % in Grade III, and 56.6 % in Grade IV glioma patients. 
Good seizure control and tolerance was demonstrated by levetiracetam. Phenytoin/carbamazepine 
were poorly tolerated due to adverse events. AED discontinuation was done in 54 patients and 14 
patients developed seizures within 6 months and again needed AED. 
Conclusion: Effective prophylaxis of seizure and acceptable adverse event profile are to be considered 
significantly in AEDs selection. Lower cognitive impairment risk and renal excretion associated with 
newer AEDs make them better than older therapeutic agents for epilepsy control in brain tumour 
patients. 
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Epilepsy is typical in brain tumour patients, and 
its control plays imperative part in clinical 
management. Convulsions add up considerable 
morbidity in brain tumour patients [1]. Epilepsy in 
brain tumour patients are mostly symptomatic 
and localization associated, showing as either 
simple or complex seizures with/without 
secondary generalization. 
 
A variety of factors influence epileptogenesis in 
brain tumour patients, namely tumour location 
and type, peritumoural environmental changes, 
and genetic factors. Hurdles of epilepsy medical 
treatment in brain tumour patients encompass 
the epilepsy refractoriness, which may be due to 
potential interactions of antiepileptic drugs 
(AEDs) as well as chemotherapeutic agents; 
multidrug-resistance proteins; and potential 
cognitive side-effects on utilization of AED 
besides prior damage to brain from radiotherapy 
or surgery [2,3]. 
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The brain tumour incidence in epilepsy patients 
is around 4 %. The seizure frequency is around 
30 % or more in brain tumour patients, relying 
upon tumour type. Epilepsy is the major medical 
sign of tumour in nearly 30 – 50 % of brain 
tumour patients; 10 – 30 % of patients develop 
epilepsy during the tumour course [2-6]. 
 
There is a dearth of studies concerning seizures 
related to glioma. Our study objective was to 
elucidate outcomes of treatment and 





This single center retrospective study was 
conducted at Department of Neurosurgery at 
Yichang Central People’s hospital, China over 
the period, August 2009 to September 2015. 
 
One hundred and nineteen successive patients 
having supratentorial gliomas in the Neurological 
Surgery Division of the hospital, in China, 
between August 2009 and September 2015 were 
included. Our study included 46 female and 73 
male patients (average age: 57 years). All of the 
cases had pathologically confirmed diagnosis. 
Altogether, 98 astrocytic plus 21 oligodendroglial 
tumours were present. The summary of patient 
characteristics were mentioned in Table 1. Since 
our center has no standard guidelines set for 
AED utilization, the particular AED used, relied 
upon preference of clinicians. Prophylactic AED 
treatment was customarily initiated prior to 
surgery. Phenytoin was typically chosen for the 
seizure prophylaxis during surgery. To 
accomplish stable concentration in serum, 
phenytoin was initiated 2 or 3 days prior to 
surgery and proceeded for 6 days post-surgery. 
In cases of adverse reactions to phenytoin and 
inadequately controlled seizures by phenytoin, 
patients were prescribed phenobarbital via 
intramuscular injection or suppository during 
surgery. 
 
Post-surgery, all of the patients with WHO - 
Grade III or Grade IV tumours were on treatment 
with irradiation along with temozolomide adjuvant 
concurrently, as per Stupp protocol [7], while 
patients having Grade II tumours were on simple 
observation. Our study received Ethics 
Committee approval and confidentiality of 
patients was strictly maintained. Data were 
collected from medical records. The clinical as 
well as demographics variables obtained were 
noted below: age, sex, histology, seizure onset 





Values are expressed as numbers and 
percentage. Fisher’s exact and Chi square tests 
were used for analysis of difference in seizure 
incidence as per WHO Grades, histology, 
location as well as tumour number, age, and sex. 
Analysis of collected data was performed using 
SPSS v16.0 (SPSS Inc, Chicago, USA). P ≤ 0.05 




Overall, 83 patients died by the time of final 
followup. Post-surgery median survival time for 
all of the patients was 20.2 months. The median 
follow up duration was noted to be 39.6 months 
(ranging from 3.7 – 84.2 months) for 36 surviving 
patients.  
 
Preoperative seizure incidence 
 
In 29 (24.4 %) patients, the presenting symptom 
was seizure. No significant statistical difference 
in the seizure incidence as primary symptom, 
among patients having oligodendroglia tumours 
(40.9 %) vs. astrocytic tumours (22.7 %); (p = 
0.145) was noted. Seizure incidence in patients, 
as per WHO grade were as follows: Grade II 
tumours 47.2 %; Grade III tumours 28.4 %; and 
Grade IV tumours 19.6 %. The seizure incidence 
was significantly higher in patients having Grade 
II tumours than patients having Grade IV tumours 
(p = 0.026). Seizures were seen most commonly 
in younger (< 50 yrs, 54.1 %) than older patients 
(≥ 50 yr, p < 0.001). Non-significant inclination for 
frontal lobe tumours to exhibit more frequent 
onset of seizures than the tumours present in 
other regions (p = 0.095). The clinical/ 
demographic characteristics are presented in 
Table 1. The seizure incidence as primary 
symptom and pertinent characteristics of patients 
are presented in Table 2. 
 
Besides 29 patients, whose presenting symptom 
was seizures, additional 10 patients (8.4 %) 
developed seizures in between their first visit and 
surgery. AED was given quickly post one seizure 
had happened in all the patients having seizures. 
Phenytoin was the widely utilized AED (48.2 %), 
however physicians likewise as often as possible 
chose valproic acid (24.1 %) and phenobarbital 
(20.7 %). 
 
Out of 80 patients with no seizures, 49 patients 
were given AED prophylactically prior to surgery. 
Phenytoin was the most widely utilized AED 
(36.8 %) for the prophylactic use; however, 
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physicians likewise as often as possible chose 
phenobarbital (11.6 %) and valproic acid (7.8 %). 
 
Table 1: Clinical/demographic characteristics of 119 
glioma patients 
 
Characteristics N (%) 
Gender 
   Male 
   Female 
Histology 
   Glioblastoma multiformae 
   Anaplastic oligodendroglioma 
   Anaplastic astrocytoma 
   Oligodendroglioma 
   Diffuse astrocytoma 
Location 
   Frontal 
   Temporal 
   Parietal 
   Basal ganglia 
   Occipital 
   Thalamus 
Therapy post-surgery 
   Observation only 





















Table 2: Seizure incidence in 119 glioma patients 
 





   Male (73) 
   Female (46) 
Age 
   < 50 yrs (32) 
   ≥ 50 yrs (87) 
Histology 
   Oligodendroglial tumors     
   (22) 
   Astrocytic tumor (97) 
Location (Present/Absent) 
   Frontal (59/60) 
   Temporal (31/88) 
   Parietal (15/104) 
   Basal ganglia (9/110) 
   Occipital (7/112) 
   Thalamus (4/115) 
WHO Grade 
   II (19) 
   III (20) 
   IV (80) 
Multiplicity 
   Solitary (98) 
















































WHO = World Health Organization; * Statistically 
significant difference with respect to Grade II and IV 
tumors 
 
Seizures amid early post-operative phase 
 
During surgery, all the patients were given AED 
prophylactically. Most of the patients received 
phenytoin (85.7 %). The rest were given 
Phenobarbital (intramuscular injection/suppose-
tory; 11.8 %), oral valproic acid (1.6 %), and 
zonisamide (0.8 %). Ten patients  (8.4 %) 
developed seizures amid initial postoperative 
week. Patients with seizure history prior to 
surgery experienced higher risk (17.2 %) than 
that of others significantly (5.2 %, p = 0.045). The 
seizures happened more often during surgery 
day (36.9 %). The seizure incidence seen in 
phenobarbital-treated patients (21.4 %) was 
greater than patients on phenytoin (6.9%); there 
was no statistically significant difference (p = 
0.266). 
 
Seizures amid follow up 
 
By the last follow up period, 73 (61.3 %) patients 
developed seizures. Seizures were seen most 
commonly in younger (< 50 yrs, 84.1 %) than 
older patients (≥ 50 yrs, 52.6 %, p < 0.003). The 
main region with significant association with 
greater seizure incidence was frontal lobe (p = 
0.035). Overall seizure incidence and pertinent 
characteristics of patients are presented in Table 
3. 
 
Table 3: Overall seizure incidence in glioma patients 
 





   Male (73) 
   Female (46) 
Age 
   < 50 yrs (32) 
   ≥ 50 yrs (87) 
Histology 
   Oligodendroglial tumors (22) 
   Astrocytic tumor (97) 
Location (involved/not) 
   Frontal (59/60) 
   Temporal (31/88) 
   Parietal (15/104) 
   Basal ganglia (9/110) 
   Occipital (7/112) 
   Thalamus (4/115) 
WHO Grade 
   II (19) 
   III (20) 
   IV (80) 
Multiplicity 
   Solitary (98) 














































WHO = World Health Organization; * Statistically 
significant difference with respect to Grade II and IV 
tumors 
 
Post-surgery, 12 patients didn’t need any AED at 
any ailment phase; the rest of the 107 patients 
were given AED for seizure prophylaxis/control. 
Out of these patients, 34 (28.6 %) needed 
three/more AEDs for seizure control. Phenytoin 
was the most widely utilized AED (n = 60) 
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postoperatively, followed by phenobarbital (n=58) 
and valproic acid (n = 56). Various patients 
likewise got carbamazepine (n = 14). At the point 
when seizures were not under control by those 
AEDs, levetiracetam (n = 20) or gabapentin (n = 
4) is included. Phenytoin usage lead to adverse 
effects customarily and seizure control failure 
often. Though valproic acid had lesser adverse 
effects, it poorly controlled seizures. 
Phenobarbital has substantial adverse event 
incidence, however controlled seizures superior 
to phenytoin and valproic acid. Carbamazepine 
showed good control of seizures, yet it was 
withdrawn often because of adverse effects. Skin 
rashes (phenytoin), dizziness (carbamazepine) 
and liver dysfunction (phenobarbital) were the 
common adverse effects. Interestingly, 
levetiracetam demonstrated good seizure control 
and was tolerated well, with withdrawn in one 
patient (somnolence). 
 
Out of 80 patients with none of the preoperative 
seizures, 15 patients withdrew AED by the first 
post-operative week whereas the rest of 65 
patients were given AED on a more extended 
period. Time to first seizure post-surgery as per 
prophylactic AED duration is depicted in Figure 
1.  
 
Figure 1: Time difference in first post-operative 
seizure with (dotted line) and without (solid line) 
prophylactic antiepileptic drugs beyond 1 week post-
surgery in patients with no preoperative seizure 
history. 
 
No significant time difference to first seizure post-
surgery with/ without AED prophylaxis after 1 
week post-surgery among patients with no 
preoperative seizure history was noted (log rank 
p = 0.584). AED continuation beyond first post-
operative week granted no added benefit. 
Besides 15 patients, who discontinued AED, 39 
additional patients discontinued later. Out of 
those 54 patients, 14 developed epileptic 
seizures within 6 months and again needed AED. 
The rest of 40 patients experienced no seizures 
and hence got none of the AEDs amid followup 





Primary brain tumours have greater seizure 
incidence than metastatic tumours [8]. In the 
present study, around 65 % of the patients 
having supratentorial gliomas developed 
epilepsy. It was recently reported that glutamate 
released via glioma cells might be a potential 
cause of seizures in glioma patients [9]. Despite 
the fact that the exact way is unclear regarding 
epileptogenesis, tumours close to cortex and 
gradually progressive tumours accounted for 
higher seizure incidence [10]. In the present 
study, patients having oligodendroglia tumours 
(that habitually penetrate the cortex), had a high 
seizure incidence than that of astrocytic tumours. 
Also, the patients with the low grade tumours 
additionally demonstrated high seizure incidence. 
This information show that the patients who are 
relied upon for longer survival have a greater 
seizure risk. In this manner, seizure control is a 
central point in keeping up quality of life of 
patients having glioma. 
 
Recently, researchers revealed an exceedingly 
low seizure incidence amid craniotomy without 
AEDs [11,12]. Lwu et al demonstrated 3 % of 
patients experiencing seizures during 
perioperative period with none of the AEDs, while 
noting no seizures on AED prophylaxis [11]. This 
may be an underestimate of seizure incidence as 
they included only the patients having malignant 
glioma and no seizure history. Nonetheless, it is 
critical to take into account the need for AEDs in 
perioperative seizure prophylaxis from cost and 
benefit point of view. Contrary to the above 
report, in this study, 8.4 % developed seizures in 
first week post craniotomy, despite the fact that 
all patients got prophylactic AEDs. Nearly 5.2 % 
of patients with malignant tumours and no 
seizure history developed perioperative seizures. 
The greater perioperative seizure incidence in 
the patients on prophylactic AED compared to 
what was noted in Lwu et al study patients who 
were on no prophylaxis brings up issue of 
justified prophylactic utilization of AED in 
perioperative seizure control. Randomized trials 
are needed to elucidate if AEDs are fundamental 
in perioperative seizures prophylaxis in case of 
patients with no seizure history. On the other 
hand, there is supposedly a high seizure 
incidence amid awake craniotomy [13]. Besides, 
seizures amid awake surgery might interfere with 
neurological function monitoring [14]. Though 
fact that the seizure incidence might be low amid 
craniotomy, it is likely prophylactic AEDs are 
prescribed in surgeries of that type. 
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In the present study, phenytoin was the widely 
utilized drug in perioperative seizure prophylaxis. 
Lately, researchers have demonstrated 
levetiracetam to be effective in seizure 
prophylaxis amid and not long after craniotomy 
[15]. Besides, levetiracetam is allegedly better 
than phenytoin for seizure prophylaxis during 
surgery [16]. 
 
In the event that seizures were very much in 
control amid surgery, we proceeded with the 
same AED in postoperative seizure prophylaxis 
in many patients. In this way, phenytoin was the 
most widely utilized AED postoperatively. 
However, phenytoin was very poorly tolerated 
and as a result, needed withdrawal within 2 
months in greater than half of the patients. More 
regular reasons for withdrawal were adverse 
effects (rash, liver dysfunction) than 
unsatisfactory control of seizures. 
 
Rash and dizziness were the most common 
reasons for carbamazepine withdrawal. Also, a 
few patients were on this agent due to poor 
acceptability. Levetiracetam acceptability was 
noted to be excellent with satisfactory seizure 
control and adverse events of lesser frequency. 
Although, significantly more number of 
psychiatric or behavioral adverse events were 
reported to be caused by levetiracetam than by 
gabapentin or lamotrigine [17]. Fortunately, none 
of the patients experienced the above kinds of 
adverse effects and in any case, it is important to 
be aware of such effects while utilizing 
levetiracetam for seizure control. 
 
In spite of the fact of secure withdrawal of AEDs 
in 39/119 patients (32.8 %), more than two AEDs 
were needed for seizure control in 34/119 
patients (28.6 %). These outcomes show how 
troublesome the seizure control can be in glioma 
patients. Additionally, during treatment, it is 
critical to watch out for interactions amongst 
AEDs and different drugs utilized for brain 
tumour treatment. The majority of the already 
accessible AEDs are metabolized by means of 
the cytochrome P450 pathway. Some AEDs 
influence the action of that enzyme. For instance, 
valproic acid inhibits CYP 2C19 whereas 
phenytoin and phenobarbital induces CYP 3A4 
[18]. Then again, a significant number of the 
agents that are often used for brain tumour 
treatment are additionally metabolized via this 
pathway and might likewise influence it. CYP 
3A4 induction by dexamethasone [19] and its 
reduction by cimetidine [20] are well known. Also, 
valproic acid inhibits glucuronidation while 
carbamazepine, phenytoin and phenobarbital 
induce it. Unstable AED concentrations due to 
such interactions leads to unsatisfactory seizure 
control. It is vital to consider adverse event risk 
or activity reduction of anti-cancer drugs due to 
metabolic interactions amongst AEDs and anti-
cancer agents. Levetiracetam and gabapentin 
are not metabolized and are generally 
discharged by the kidneys. Hence they do not 
have much interaction with other therapeutic 
agents and are therefore safer to use with other 
anticancer drugs. 
 
Klein et al earlier revealed that patients having 
glioma demonstrate poor cognitive function when 
compared to healthy controls. It was also 
described that treatment with AEDs, as opposed 
to seizure recurrence, negatively influences 
cognitive function [21]. To prevent AED adverse 
effects, along with deterioration of cognition, the 
American Academy of Neurology Quality 
Standards Subcommittee has developed 
guidelines which prescribe tapering and 
discontinuation of AED beyond the first post-
operative week in the patients having no seizure 
history [22]. In the present study, AED 
continuation beyond 1 week post craniotomy in 
the patients with no seizure history did not 
prevent postoperative seizure onset. In this way, 
our outcomes reinforce the above mentioned 
guidelines in regards to AED prophylaxis for the 
patients with no prior seizures. Nevertheless, it is 
crucial to take account that no seizures prior to 
craniotomy does not ensure no seizure course 
post-surgery. In the present study, greater than 
40 % of the patients with no seizure prior to 
surgery experienced the seizures post-surgery, 
despite on AEDs. 
 
Epilepsy in brain tumour patients is a distinctive 
form where the seizure risk might change as per 
tumour status. Recurrence of tumour and 
alterations in encompassing brain tissue due to 
therapy, for example, necrosis post radiation 
treatment, might change the seizure risk. Hence, 
medication discontinuation should be examined 
carefully, despite the fact that these drugs can 
lead to decreased cognitive function. Newer 
AEDs, namely levetiracetam, gabapentin and 
lamotrigine on the other hand, are apparently 
safe with respect to the cognitive function [23]. 
Levetiracetam, apparently enhances memories in 
the animal models [24] and enhances quality of 
life in brain tumour patients having epilepsy [25]. 
Of late, verbal memory improvement in high-
grade glioma patients on levetiracetam has been 
demonstrated [26]. We prescribe picking this 
AED in patients where AED discontinuation is not 
advisable due to unsteady conditions of tumour. 
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Limitations of the study 
 
Certain innate limitations need consideration 
during results interpretation of of present study. 
This single-center study has limited number of 
patients, hence the results generalization should 
be done with great care. We were not able to 
assess all variables and were limited by the 
treating physicians in regards to completeness of 





Effective prophylaxis of seizure and acceptable 
adverse event profile should be considered 
significant in AEDs selection. Additionally, in 
brain tumour patients suffering epilepsy, it is 
important to consider drug interactions with other 
therapeutic agents and cognitive impairment risk. 
The lower cognitive impairment risk and the renal 
discharge associated with newer AEDs make 
them more suitable than the older therapeutic 
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